Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0038362 (stomatitis)
 8,852 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Thirty patients with Behcet's disease were treated with immunosuppressive drugs, 25 with Imuran, 5 with Leukerin and 2 with both these drugs. Daily administration of 50-75 mg of Imuran over a period of 1 year alleviated the ocular symptoms in 16% of patients, was slightly effective in 20%, and ineffective in 64%. Imuran therapy was also seen to alleviate the extraocular pathology, such as stomatitis, erythema, and arthralgia. Leukerin proved difficult to prescribe over a long period because of severe side effects.
 ...
PMID:Immunosuppressive treatment of Behcet's disease. 125 Feb 36

Behcet's disease is a systemic inflammatory disease of unknown etiology which usually occurs as a trait of symptoms: aphatous stomatitis, genital ulcerations and eye disease. Characteristic manifestations are frequent: erythema nodosum, arthralgias, arthritis, myalgias, phlebothrombosis and nervous system disorders as well as disorders of other organs and systems. Behcet's disease was discovered in 1937 for the first time by dermatovenerologist Hulusi Behcet (1889 - 1948) after whom it was named Behcet's disease or Behcet's syndrome. At the beginning of the disease the diagnosis is uncertain because of different schedule of certain manifestations and a long period up to the full clinical picture manifestation. As it is well known, the main changes occur at the buccal mucosa in a form of a recidivant aphthous and herpetiformis lesions. Genital ulcerations are present in 64 to 87% of patients. Changes which occur on eyes may be present in 28 - 80% of patients and may dominate the clinical picture. The skin is affected in about 50% of patients. Manifestations on joints occur at major joints of the lower limbs. Sometimes gastrointestinal manifestations occur as enterocolitis and ulcerous colitis. Nervous system lesions have poor prognosis. The treatment involves: acute exacerbations with multisystemic manifestations by utilization of non-steroid anti-inflammatory drugs and immunosuppressive preparations. Corticosteroids are used in severe cases.
 ...
PMID:[Behcet's disease--clinical picture and treatment]. 869 3

The authors review the literature on aetiopathogenesis and therapeutic management of recurrent aphthous stomatitis. The data regarding the role of genetic, nutritional and microbiological factors in the genesis of recurrent aphthous stomatitis has been particularly examined. Despite significant associations with some antigens HLA have been reported in Southern Europe, there is no clear genetic predisposition in recurrent aphthous stomatitis. Several studies have analyzed the importance of iron, folic acid and vitamin B12 deficiencies, gluten intolerance and sensitivity to certain foods in the triggering of recurrent aphthous stomatitis however the results have been controversial. Recently, it has been suggested that recurrent aphthous stomatitis could be caused by reactivation of varicella-zoster virus and/or cytomegalovirus but these viruses may be reactivated by the immunodysregulation known to underlie recurrent aphthous stomatitis. Moreover, antiviral drugs appear to have only an equivocal effect on recurrent aphthous stomatitis. Recurrent aphthous stomatitis is probably determined by immunological mechanisms although there actually no unifying hypothesis which attempt to integrate the results of the many immunologic studies on recurrent aphotous stomatitis. Moreover, the target antigen and the cause of recurrences of recurrent aphthous stomatitis are still unknown. As far as the management of this disease it is important to recognize recurrent aphthous stomatitis secondary to systemic diseases like Behcet's syndrome, gluten enteropathy and haematinics deficiencies. Subsequently, the symptoms can be reduced with several drugs (mainly topical corticosteroids) but there are no effective therapies preventing recurrences.
 ...
PMID:[Recurrent aphthous stomatitis: current etiopathogenetic and therapeutic concepts]. 872 Dec 6

To assess the frequency and clinical characteristics of methotrexate (MTX) oral toxicity in rheumatoid arthritis (RA) patients, 51 RA patients receiving MTX and 46 RA patients not receiving MTX were studied. A questionnaire, the credibility of which was tested on four separate patient groups including a group with Behcet's Syndrome, was used as a tool to determine the prevalence of stomatitis by a blind observer. In this first controlled study of the oral toxicity of MTX, prevalence of stomatitis was found in 37.2% in the group taking MTX and 19.5% in the group not taking MTX (P = 0.054). No statistical differences were detected with respect to number, duration, frequency, and site of stomatitis. Two of the 51 MTX taking patients temporarily reduced their MTX dosage and only one patient temporarily terminated MTX treatment. MTX and toxicity is usually of no major clinical concern in the treatment of RA.
 ...
PMID:The frequency and clinical characteristics of methotrexate (MTX) oral toxicity in rheumatoid arthritis (RA): a masked and controlled study. 889 64